Pharming (PHAR) Total Non-Current Liabilities (2019 - 2026)

Pharming (PHAR) has 8 years of Total Non-Current Liabilities data on file, last reported at $104.2 million in Q2 2026.

• Quarterly Total Non-Current Liabilities fell 12.22% year-over-year to $104.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $104.2 million (down 12.22% YoY) and the FY2025 annual result came in at $107.1 million, up 1.85% from the prior year.
• Total Non-Current Liabilities eased to $104.2 million in Q2 2026, from $108.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $166.1 million in Q4 2023 to a low of $135375.0 in Q3 2022.
• A 5-year average of $119.6 million and a median of $119.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 99.92% — and 2023, when it jumped 116957.8%.
• Tracing PHAR's Total Non-Current Liabilities over 5 years: stood at $161.5 million in 2022, then advanced by 2.88% to $166.1 million in 2023, then slumped by 36.71% to $105.1 million in 2024, then gained by 1.85% to $107.1 million in 2025, then declined by 2.63% to $104.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $104.2 million (Q2 2026), $108.1 million (Q1 2026), and $107.1 million (Q4 2025), per Business Quant data.